Novel markers of squamous differentiation in the urinary bladder

Wenbin Huang, Sean R. Williamson, Qiu Rao, Antonio Lopez-Beltran, Rodolfo Montironi, John N. Eble, David J. Grignon, Muhammad T. Idrees, Robert E. Emerson, Xiao Jun Zhou, Shaobo Zhang, Lee Ann Baldridge, Noah Hahn, Mingsheng Wang, Michael O. Koch, Liang Cheng

Research output: Contribution to journalArticle

Abstract

Summary Urinary bladder squamous cell carcinoma and urothelial carcinoma with squamous differentiation are often high-grade and high-stage tumors that are thought to be associated with a poorer prognosis and response to therapy compared with urothelial carcinoma without divergent differentiation. Therefore, recognition of a squamous component is increasingly important in guiding prognosis and therapy. We investigated the expression of MAC387, desmoglein-3, and TRIM29 in pure squamous cell carcinoma and urothelial carcinoma with squamous differentiation to determine whether they have utility as diagnostic biomarkers for squamous differentiation. Eighty-four cases were retrieved from participating institutions including 51 pure urinary bladder squamous cell carcinomas and 33 urothelial carcinomas with squamous differentiation. MAC387, desmoglein-3, and TRIM29 antibodies demonstrated positive staining in pure squamous cell carcinoma in 51 (100%), 46 (90%), and 48 (93%) cases, respectively. Urothelial carcinoma with squamous differentiation showed reactivity for MAC387, desmoglein-3, and TRIM29 in the squamous component for 32 (97%), 26 (79%), and 32 (97%) cases, respectively. MAC387 demonstrated a sensitivity of 99% and a specificity of 70% for squamous differentiation, whereas desmoglein-3 yielded a sensitivity of 86% and a specificity of 91%. No urothelial component showed greater than 10% labeling for desmoglein-3. TRIM29 labeling showed a sensitivity of 95%, but a poorer specificity of 33%. In summary, MAC387 and desmoglein-3 are reliable diagnostic markers for supporting the morphologic impression of squamous differentiation in urinary bladder carcinoma. Desmoglein-3 shows high specificity, whereas TRIM29 was most likely to demonstrate labeling in areas without light microscopically recognizable squamous differentiation.

Original languageEnglish (US)
Pages (from-to)1989-1997
Number of pages9
JournalHuman Pathology
Volume44
Issue number10
DOIs
StatePublished - Oct 2013
Externally publishedYes

Fingerprint

Desmoglein 3
Differentiation Antigens
Squamous Cell Carcinoma
Urinary Bladder
Carcinoma
Biomarkers
Staining and Labeling
Light
Antibodies

Keywords

  • Desmoglein-3
  • MAC387
  • Squamous cell carcinoma
  • TRIM29
  • Urinary bladder
  • Urothelial carcinoma with mixed differentiation

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Huang, W., Williamson, S. R., Rao, Q., Lopez-Beltran, A., Montironi, R., Eble, J. N., ... Cheng, L. (2013). Novel markers of squamous differentiation in the urinary bladder. Human Pathology, 44(10), 1989-1997. https://doi.org/10.1016/j.humpath.2013.04.005

Novel markers of squamous differentiation in the urinary bladder. / Huang, Wenbin; Williamson, Sean R.; Rao, Qiu; Lopez-Beltran, Antonio; Montironi, Rodolfo; Eble, John N.; Grignon, David J.; Idrees, Muhammad T.; Emerson, Robert E.; Zhou, Xiao Jun; Zhang, Shaobo; Baldridge, Lee Ann; Hahn, Noah; Wang, Mingsheng; Koch, Michael O.; Cheng, Liang.

In: Human Pathology, Vol. 44, No. 10, 10.2013, p. 1989-1997.

Research output: Contribution to journalArticle

Huang, W, Williamson, SR, Rao, Q, Lopez-Beltran, A, Montironi, R, Eble, JN, Grignon, DJ, Idrees, MT, Emerson, RE, Zhou, XJ, Zhang, S, Baldridge, LA, Hahn, N, Wang, M, Koch, MO & Cheng, L 2013, 'Novel markers of squamous differentiation in the urinary bladder', Human Pathology, vol. 44, no. 10, pp. 1989-1997. https://doi.org/10.1016/j.humpath.2013.04.005
Huang W, Williamson SR, Rao Q, Lopez-Beltran A, Montironi R, Eble JN et al. Novel markers of squamous differentiation in the urinary bladder. Human Pathology. 2013 Oct;44(10):1989-1997. https://doi.org/10.1016/j.humpath.2013.04.005
Huang, Wenbin ; Williamson, Sean R. ; Rao, Qiu ; Lopez-Beltran, Antonio ; Montironi, Rodolfo ; Eble, John N. ; Grignon, David J. ; Idrees, Muhammad T. ; Emerson, Robert E. ; Zhou, Xiao Jun ; Zhang, Shaobo ; Baldridge, Lee Ann ; Hahn, Noah ; Wang, Mingsheng ; Koch, Michael O. ; Cheng, Liang. / Novel markers of squamous differentiation in the urinary bladder. In: Human Pathology. 2013 ; Vol. 44, No. 10. pp. 1989-1997.
@article{0d221594b0b348bd8fbe539c07c2c20f,
title = "Novel markers of squamous differentiation in the urinary bladder",
abstract = "Summary Urinary bladder squamous cell carcinoma and urothelial carcinoma with squamous differentiation are often high-grade and high-stage tumors that are thought to be associated with a poorer prognosis and response to therapy compared with urothelial carcinoma without divergent differentiation. Therefore, recognition of a squamous component is increasingly important in guiding prognosis and therapy. We investigated the expression of MAC387, desmoglein-3, and TRIM29 in pure squamous cell carcinoma and urothelial carcinoma with squamous differentiation to determine whether they have utility as diagnostic biomarkers for squamous differentiation. Eighty-four cases were retrieved from participating institutions including 51 pure urinary bladder squamous cell carcinomas and 33 urothelial carcinomas with squamous differentiation. MAC387, desmoglein-3, and TRIM29 antibodies demonstrated positive staining in pure squamous cell carcinoma in 51 (100{\%}), 46 (90{\%}), and 48 (93{\%}) cases, respectively. Urothelial carcinoma with squamous differentiation showed reactivity for MAC387, desmoglein-3, and TRIM29 in the squamous component for 32 (97{\%}), 26 (79{\%}), and 32 (97{\%}) cases, respectively. MAC387 demonstrated a sensitivity of 99{\%} and a specificity of 70{\%} for squamous differentiation, whereas desmoglein-3 yielded a sensitivity of 86{\%} and a specificity of 91{\%}. No urothelial component showed greater than 10{\%} labeling for desmoglein-3. TRIM29 labeling showed a sensitivity of 95{\%}, but a poorer specificity of 33{\%}. In summary, MAC387 and desmoglein-3 are reliable diagnostic markers for supporting the morphologic impression of squamous differentiation in urinary bladder carcinoma. Desmoglein-3 shows high specificity, whereas TRIM29 was most likely to demonstrate labeling in areas without light microscopically recognizable squamous differentiation.",
keywords = "Desmoglein-3, MAC387, Squamous cell carcinoma, TRIM29, Urinary bladder, Urothelial carcinoma with mixed differentiation",
author = "Wenbin Huang and Williamson, {Sean R.} and Qiu Rao and Antonio Lopez-Beltran and Rodolfo Montironi and Eble, {John N.} and Grignon, {David J.} and Idrees, {Muhammad T.} and Emerson, {Robert E.} and Zhou, {Xiao Jun} and Shaobo Zhang and Baldridge, {Lee Ann} and Noah Hahn and Mingsheng Wang and Koch, {Michael O.} and Liang Cheng",
year = "2013",
month = "10",
doi = "10.1016/j.humpath.2013.04.005",
language = "English (US)",
volume = "44",
pages = "1989--1997",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "10",

}

TY - JOUR

T1 - Novel markers of squamous differentiation in the urinary bladder

AU - Huang, Wenbin

AU - Williamson, Sean R.

AU - Rao, Qiu

AU - Lopez-Beltran, Antonio

AU - Montironi, Rodolfo

AU - Eble, John N.

AU - Grignon, David J.

AU - Idrees, Muhammad T.

AU - Emerson, Robert E.

AU - Zhou, Xiao Jun

AU - Zhang, Shaobo

AU - Baldridge, Lee Ann

AU - Hahn, Noah

AU - Wang, Mingsheng

AU - Koch, Michael O.

AU - Cheng, Liang

PY - 2013/10

Y1 - 2013/10

N2 - Summary Urinary bladder squamous cell carcinoma and urothelial carcinoma with squamous differentiation are often high-grade and high-stage tumors that are thought to be associated with a poorer prognosis and response to therapy compared with urothelial carcinoma without divergent differentiation. Therefore, recognition of a squamous component is increasingly important in guiding prognosis and therapy. We investigated the expression of MAC387, desmoglein-3, and TRIM29 in pure squamous cell carcinoma and urothelial carcinoma with squamous differentiation to determine whether they have utility as diagnostic biomarkers for squamous differentiation. Eighty-four cases were retrieved from participating institutions including 51 pure urinary bladder squamous cell carcinomas and 33 urothelial carcinomas with squamous differentiation. MAC387, desmoglein-3, and TRIM29 antibodies demonstrated positive staining in pure squamous cell carcinoma in 51 (100%), 46 (90%), and 48 (93%) cases, respectively. Urothelial carcinoma with squamous differentiation showed reactivity for MAC387, desmoglein-3, and TRIM29 in the squamous component for 32 (97%), 26 (79%), and 32 (97%) cases, respectively. MAC387 demonstrated a sensitivity of 99% and a specificity of 70% for squamous differentiation, whereas desmoglein-3 yielded a sensitivity of 86% and a specificity of 91%. No urothelial component showed greater than 10% labeling for desmoglein-3. TRIM29 labeling showed a sensitivity of 95%, but a poorer specificity of 33%. In summary, MAC387 and desmoglein-3 are reliable diagnostic markers for supporting the morphologic impression of squamous differentiation in urinary bladder carcinoma. Desmoglein-3 shows high specificity, whereas TRIM29 was most likely to demonstrate labeling in areas without light microscopically recognizable squamous differentiation.

AB - Summary Urinary bladder squamous cell carcinoma and urothelial carcinoma with squamous differentiation are often high-grade and high-stage tumors that are thought to be associated with a poorer prognosis and response to therapy compared with urothelial carcinoma without divergent differentiation. Therefore, recognition of a squamous component is increasingly important in guiding prognosis and therapy. We investigated the expression of MAC387, desmoglein-3, and TRIM29 in pure squamous cell carcinoma and urothelial carcinoma with squamous differentiation to determine whether they have utility as diagnostic biomarkers for squamous differentiation. Eighty-four cases were retrieved from participating institutions including 51 pure urinary bladder squamous cell carcinomas and 33 urothelial carcinomas with squamous differentiation. MAC387, desmoglein-3, and TRIM29 antibodies demonstrated positive staining in pure squamous cell carcinoma in 51 (100%), 46 (90%), and 48 (93%) cases, respectively. Urothelial carcinoma with squamous differentiation showed reactivity for MAC387, desmoglein-3, and TRIM29 in the squamous component for 32 (97%), 26 (79%), and 32 (97%) cases, respectively. MAC387 demonstrated a sensitivity of 99% and a specificity of 70% for squamous differentiation, whereas desmoglein-3 yielded a sensitivity of 86% and a specificity of 91%. No urothelial component showed greater than 10% labeling for desmoglein-3. TRIM29 labeling showed a sensitivity of 95%, but a poorer specificity of 33%. In summary, MAC387 and desmoglein-3 are reliable diagnostic markers for supporting the morphologic impression of squamous differentiation in urinary bladder carcinoma. Desmoglein-3 shows high specificity, whereas TRIM29 was most likely to demonstrate labeling in areas without light microscopically recognizable squamous differentiation.

KW - Desmoglein-3

KW - MAC387

KW - Squamous cell carcinoma

KW - TRIM29

KW - Urinary bladder

KW - Urothelial carcinoma with mixed differentiation

UR - http://www.scopus.com/inward/record.url?scp=84884414765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884414765&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2013.04.005

DO - 10.1016/j.humpath.2013.04.005

M3 - Article

C2 - 23806524

AN - SCOPUS:84884414765

VL - 44

SP - 1989

EP - 1997

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 10

ER -